Harmon Cyrus 4
4 · Olema Pharmaceuticals, Inc. · Filed Jul 31, 2024
Insider Transaction Report
Form 4
Harmon Cyrus
Director
Transactions
- Sale
Common Stock
2024-07-29$15.58/sh−4,066$63,348→ 752,217 total - Sale
Common Stock
2024-07-30$15.55/sh−934$14,524→ 751,283 total
Holdings
- 122,028(indirect: See Footnote)
Common Stock
Footnotes (4)
- [F1]The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person dated May 16, 2023.
- [F2]The weighted average sale price for the transaction reported was $15.58, and the range of prices was between $15.55 and $15.64. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
- [F3]The weighted average sale price for the transaction reported was $15.55, and the range of prices was between $15.55 and $15.58. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
- [F4]The shares are held by the Harmon Family Investors LLC, of which the Reporting Person is the manager.